Trends and hotspots in genetic and therapeutic research on kidney renal clear cell carcinoma: a comprehensive bibliometric study

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Kidney renal clear cell carcinoma (KIRC) is the most common subtype of kidney cancer, making up about 70–80 % of all cases. This cancer displays high molecular heterogeneity and responds poorly to standard therapies. Over the past decade, research on KIRC has shifted significantly toward genetically based treatments and precision medicine.

Aim. To analyze global trends in KIRC genetics and treatment research through a bibliometric review of the Scopus database from 2009 to 2025.

Materials and methods. The method involved collecting documents with the keyword “Kidney Renal Clear Cell Carcinoma” in English. The data were analyzed using VOSviewer software for keyword network visualization and Bibliometrix (R Studio) for descriptive analysis, including publication growth, international collaborations, affiliations, and citations. Analysis was also conducted on thematic clustering and the identification of the most influential authors and institutions.

Results. There were 870 publications across 285 sources, with an annual growth rate of 28.31 %. International collaborations made up only 9.66 %, highlighting the dominance of domestic partnerships. The most active author was Wang Y, with 58 publications and 773 citations. Three main thematic groups were identified: gene-based prognostic models, pan-cancer approaches, and molecular mechanisms of tumors. Topics like immunotherapy, multi-omics, and artificial intelligence experienced notable increases in citations.

Conclusion. KIRC global research advanced quickly toward integrating genetically based precision therapies. This study provided a strategic foundation for research planning, funding, and international collaboration in molecular oncology.

About the authors

Danang Prasetyaning Amukti

Alma Ata University

Author for correspondence.
Email: danangpa@almaata.ac.id

Department of Pharmacy, Faculty of Health Science

Indonesia, Yogyakarta

Nurul Kusumawardani

Alma Ata University

Email: danangpa@almaata.ac.id

Department of Pharmacy, Faculty of Health Science

Indonesia, Yogyakarta

Daru Estiningsih

Alma Ata University

Email: danangpa@almaata.ac.id

Department of Pharmacy, Faculty of Health Science

Indonesia, Yogyakarta

Emelda Emelda

Alma Ata University

Email: danangpa@almaata.ac.id

Department of Pharmacy, Faculty of Health Science

Indonesia, Yogyakarta

Moch Saiful Bachri

Ahmad Dahlan University

Email: danangpa@almaata.ac.id

Faculty of Pharmacy

Indonesia, Yogyakarta

Ria Indah Pratami

Ahmad Dahlan University

Email: danangpa@almaata.ac.id

Faculty of Pharmacy

Indonesia, Yogyakarta

References

  1. Ren H., Chen X., Ji M. et al. CRYAB is upregulated and predicts clinical prognosis in kidney renal clear cell carcinoma. IUBMB Life 2025;77(1):e2938. doi: 10.1002/iub.2938
  2. Zhang J., Zou B., Geng Y. et al. TRIM36 serves as a prognostic indicator linked to immune infiltration in KIRC. Heliyon 2025;11(4):e42540. doi: 10.1016/j.heliyon.2025.e42540
  3. Jia C., Wang T., Cui D. et al. A metagene-based similarity network fusion approach for multi-omics data integration identified novel subtypes in renal cell carcinoma. Brief Bioinform 2024;25(6):bbae606. doi: 10.1093/bib/bbae606
  4. Kim I.H., Lee H.J. The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective. Biomedicines 2022;10(2):251. doi: 10.3390/biomedicines10020251
  5. Wang J., Chang H., Su M. et al. Identification of HGD and GSTZ1 as biomarkers involved metabolic reprogramming in kidney renal clear cell carcinoma. Int J Mol Sci 2022;23(9):4583. doi: 10.3390/ijms23094583
  6. Xu K., Li D., Ji K. et al. Disulfidptosis-associated LncRNA signature predicts prognosis and immune response in kidney renal clear cell carcinoma. Biol Direct 2024;19(1):71. doi: 10.1186/s13062-024-00517-7
  7. Li C., Zhang W., Fang T. et al. Identification of the Prognostic value among suppressor of cytokine signaling family members in kidney renal clear cell carcinoma. Front Mol Biosci 2021;8:585000. doi: 10.3389/fmolb.2021.585000
  8. Mehdi A., Riazalhosseini Y. Epigenome aberrations: emerging driving factors of the clear cell renal cell carcinoma. Int J Mol Sci 2017;18(8):1774. doi: 10.3390/ijms18081774
  9. Heyliger S.O., Soliman K.F.A., Saulsbury M.D., Reams R.R. The identification of zinc-finger protein 433 as a possible prognostic biomarker for clear-cell renal cell carcinoma. Biomolecules 2021;11(8):1193. doi: 10.3390/biom11081193
  10. Zhang Z., Chen H., Yan D. et al. Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade. Oncogenesis 2023;12(1):37. doi: 10.1038/s41389-023-00482-2
  11. Ye Z., Zeng D., Zhou R. et al. Tumor microenvironment evaluation for gastrointestinal cancer in the era of immunotherapy and machine learning. Front Immunol 2022;13:819807. doi: 10.3389/fimmu. 2022.819807
  12. Xia Q.D., Li B., Sun J.X. et al. Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. Front Oncol 2023;13:1096341. doi: 10.3389/fonc.2023.1096341
  13. Chen M., Gao Y., Cao H. et al. Comprehensive analysis reveals dual biological function roles of EpCAM in kidney renal clear cell carcinoma. Heliyon 2023;10(1):e23505. doi: 10.1016/j.heliyon.2023.e23505
  14. Chen Z., Chen C., Li L. et al. The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Comput Struct Biotechnol J 2021;19:5428–42. doi: 10.1016/j.csbj.2021.09.029
  15. Amukti D.P., Irham L.M., Surono S. et al. Atherosclerosis research in the genomic era: global trends from 1983 to 2024. Bulgarian Cardiology [Internet] 2024;30(4):40–8. Available at: https://journal.bgcardio.org/article/143367/
  16. Irham L.M., Amukti D.P., Adikusuma W. et al. Applied bioinformatics in drug discovery and drug development: Bioinformatic analysis 1996–2024. Eds.: S. Zubaidah, M.F. Saifuddin, G.S. de Carvalho et al. BIO Web Conf [Internet] 2024;148:01003. Available at: https://www.bio-conferences.org/10.1051/bioconf/202414801003
  17. Irham L.M., Amukti D.P., Adikusuma W. et al. Trends in drug repurposing for chronic hepatitis-B infection: bibliometric-based approach 1990–2024. In: BIO Web of Conferences. EDP Sciences; 2025.
  18. Prasetyaning A., Muhammad I., Surono S. et al. International developments in atherosclerosis disease research using precision medicine (1994–2024): a bibliometric analysis. Scr Med (Brno) [Internet] 2025;56(2):395–404. Available at: https://scindeks.ceon.rs/ Article.aspx?artid=2490-33292502395A
  19. Chen S., Ding Y. A bibliometric analysis on the risk factors of cancer. Genes, Chromosomes, Cancer 2025;64(1):e70019. doi: 10.1002/gcc.70019
  20. Ge Y., Chao T., Sun J. et al. Frontiers and hotspots evolution in psycho-cardiology: a bibliometric analysis from 2004 to 2022. Curr Probl Cardiol 2022;47(12):101361. doi: 10.1016/j.cpcardiol.2022.101361
  21. Yeerlan J., He B., Hu X., Zhang L. Global research trends and hotspots for ferroptosis, necroptosis, and pyroptosis in Alzheimer’s disease from the past to 2023: a combined bibliometric review. J Alzheimers Dis Rep 2024;8(1):129–42. doi: 10.3233/ADR-230092
  22. Zheng C., Wen X., Zhang L. et al. Research situation, hot spots, and global trends of melasma therapy: Bibliometric insights and visual analysis from 2000 to 2023. J Cosmet Dermatol 2024;23(11):3667–83. doi: 10.1111/jocd.16438
  23. Yang M., Gong C., Song K. et al. APPL1 is a prognostic biomarker and correlated with Treg cell infiltration via oxygen-consuming metabolism in renal clear cell carcinoma. Oxid Med Cell Longev 2023;2023:5885203. doi: 10.1155/2023/5885203
  24. Xu T., Wei D., Yang Z. et al. ApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway. Arch Biochem Biophys 2023 Jul 15;743:109642. doi: 10.1016/j.abb.2023.109642
  25. Luo J., Yi T., Wang Y. et al. ESM1 promote proliferation, invasion and angiogenesis via Akt/mTOR and Ras pathway in kidney renal clear cell carcinoma. Sci Rep 2025;15(1):4902. doi: 10.1038/s41598-024-82400-z
  26. Lin L., Gong S., Deng C. et al. PTK6: An emerging biomarker for prognosis and immunotherapeutic response in clear cell renal carcinoma (KIRC). Heliyon 2024;10(7):e29001. doi: 10.1016/j.heliyon.2024.e29001
  27. Li S., Wang X., Wang Q. et al. Effects and prognostic values of circadian genes CSNK1E/GNA11/KLF9/THRAP3 in kidney renal clear cell carcinoma via a comprehensive analysis. Bioengineering (Basel) 2022;9(7):306. doi: 10.3390/bioengineering9070306
  28. Zhang C., Feng X., Wang C. et al. Bibliometric analysis of scientific publications in rheumatology journals from China and other top-ranking countries between 2007 and 2017. PeerJ 2019;7:e6825. doi: 10.7717/peerj.6825
  29. enbari Oskouie I., Alemi H., Khavandgar N. et al. Global research trends on colorectal cancer (2014–2023): a scientometric and visualized study. Arch Iran Med 2024;27(10):563–72. doi: 10.34172/aim.31944
  30. Zheng S., Wang Y., Geng J. et al. Global trends in research on MOG antibody-associated disease: bibliometrics and visualization analysis. Front Immunol 2024;15:1278867. doi: 10.3389/fimmu.2024.1278867
  31. Hashimoto H., Sekine M., Nishizaki Y et al. Global trends in the value of author order across medical publications: a cross-sectional bibliometric study. Clin Transl Sci 2025;18(2):e70157. doi: 10.1111/cts.70157
  32. Nagy Á., Munkácsy G., Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep 2021;11(1):6047. doi: 10.1038/s41598-021-84787-5
  33. Chang S., Yim S., Park H. The cancer driver genes IDH1/2, JARID1C/KDM5C, and UTX/KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med 2019 Jun 20;51(6):1–17. doi: 10.1038/s12276-019-0230-6
  34. Qin C., Liu S., Zhou S. et al. PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. Front Immunol 2023;14:1114572. doi: 10.3389/fimmu.2023.1114572
  35. Zhu H., Lu J., Zhao H. et al. Functional long noncoding RNAs (lncRNAs) in clear cell kidney carcinoma revealed by reconstruction and comprehensive analysis of the lncRNA-miRNA-mRNA regulatory network. Med Sci Monit 2018;24:8250–63. doi: 10.12659/MSM.910773
  36. Wang J., Chang H., Su M. et al. Identification of HGD and GSTZ1 as biomarkers involved metabolic reprogramming in kidney renal clear cell carcinoma. Int J Mol Sci 2022;23(9):4583. doi: 10.3390/ijms23094583
  37. Li X., Rokohl A.C., Ju X. et al. Global research trends in the treatment of squamous cell carcinoma over the past decade: a bibliometric analysis. Adv Ophthalmol Pract Res 2024;4(4):209–15. doi: 10.1016/j.aopr.2024.08.001
  38. Yang G.H., Ma X.D., Wei X.F. et al. A Novel KIF4A-related model for predicting immunotherapy response and prognosis in kidney renal clear cell carcinoma. Comb Chem High Throughput Screen 2025;28(4):691–710. doi: 10.2174/0113862073296897240212114403
  39. Sun W., Xu P., Gao K. et al. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer. J Cell Mol Med 2024;28(8):e18309. doi: 10.1111/jcmm.18309
  40. Gao Y., Hou H., Cang Q. et al. Global research trends and future directions for buckwheat as a smart crop: a bibliometric and content analysis. Foods 2024;13(24):4068. doi: 10.3390/foods13244068
  41. Han M., Niu H., Duan F. et al. Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis. Front Oncol 2024;14:1383805. doi: 10.3389/fonc.2024.1383805

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.